retatrutide triple agonist obesity trial Experimental drug cut weight by nearly 30% in Phase 3 trials, outperforming approved therapies, Eli Lilly says Retatrutide—A Game Changer in Obesity

The 0.5 mL syringe has markings every single unit (1 IU increments) and tops out at 50 units

Things to take into account and can differentiate your company in this space: In case you were wondering, you can not risk it when working in healthtech

Randomized controlled clinical trials investigating the use of semaglutide in patients with alcohol use disorders (AUD) and comorbid obesity are currently underway, based on the potential of GLP-1R agonists for AUD treatment [113]

They work on one hormone receptor and produce about 15% weight loss

Just dont inject them right next to each other (give those injections a little room to breathe!)